Search results
Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why
Zacks via Yahoo Finance· 7 months agoInovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase...
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
Zacks via Yahoo Finance· 12 months agoINOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare...
Inovio Pharmaceuticals (INO) Q3 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO)Q3 2022 Earnings CallNov 08,...
Metaverse-based Game Infinity Arena Announces INO Date and Roadmap
NewMediaWire via Yahoo Finance· 2 years agoHanoi, Vietnam - (NewMediaWire) - September 14, 2022 - Infinity Arena, a play-to-earn [P2E] and...
Inovio Pharma Stops Work On INO-4800 As COVID-19 Heterologous Booster
Benzinga via Yahoo Finance· 2 years agoInovio Pharmaceuticals Inc (NASDAQ: INO) discontinued its internally funded efforts to develop...
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Motley Fool via Yahoo Finance· 6 days agoSome investors might remember Inovio Pharmaceuticals (NASDAQ: INO); others might not. The small-cap...
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 2 months agoThe consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical...
Within A Month After Pulling Plug On COVID-19 Booster Study, Inovio Shelves Two More Infectious...
Benzinga via Yahoo Finance· 1 year agoInovio Pharmaceuticals Inc (NASDAQ: INO) has agreed with its collaborator, the Coalition for...
Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease
Benzinga via Yahoo Finance· 2 years agoInovio Pharmaceuticals Inc (NASDAQ: INO) announced interim results from an ongoing Phase 1/2 trial...
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's...
Zacks via Yahoo Finance· 2 years agoInovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings...